Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study
Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3358-3365
Open Access | Times Cited: 22

Showing 22 citing articles:

JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis
Shivani Mattay, Mohammad Zamani, Dany Saturno, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 5, pp. 961-970.e12
Closed Access | Times Cited: 23
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy
Xiaohuan Wei, Yuanyuan Liu
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 7
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Ennio Giulio Favalli, Gabriella Maioli, Roberto Caporali
Drugs (2024) Vol. 84, Iss. 8, pp. 877-894
Open Access | Times Cited: 6
Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
Se Rim Choi, Anna Shin, You‐Jung Ha, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 13
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 10-10
Open Access | Times Cited: 4
Stem Cell‐Derived Exosomes as Nanotherapeutics for Inflammatory Diseases
Xinyu Wei, Qingyi Wang, Wen Wen, et al.
MedComm – Future Medicine (2025) Vol. 4, Iss. 1
Open Access
JAK-STAT Signaling in Autoimmunity and Cancer
Sana Parveen, Mena Fatma, Snober S. Mir, et al.
ImmunoTargets and Therapy (2025) Vol. Volume 14, pp. 523-554
Open Access
The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study
A Calvo García, Esther Ramírez Herráiz, Irene María Llorente Cubas, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2517-2517
Open Access | Times Cited: 3
A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
Rouhin Sen, Maria Riofrio, Jasvinder A. Singh
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 6, pp. 687-714
Closed Access | Times Cited: 3
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study
Po‐Ku Chen, Shih‐Hsin Chang, Yi‐Ming Chen, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2503-2511
Closed Access | Times Cited: 3
Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
Shuhei Yoshida, Masayuki Miyata, Eiji Suzuki, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study
A Calvo García, Esther Ramírez Herráiz, Irene María Llorente Cubas, et al.
(2024)
Open Access | Times Cited: 2
Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook
Koshiro Sonomoto, Yoshiya Tanaka
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1325-1342
Closed Access | Times Cited: 5
Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis
Justus G. Garweg, Kim A. Straessle
Ocular Immunology and Inflammation (2024), pp. 1-8
Closed Access
Selective JAK-Inhibitors in Spondyloarthritis
Konstantinos D Vassilakis, Konstantina Magiouf, Stefan Siebert, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 27-27
Open Access
Incidence Rates of Infections in Rheumatoid Arthritis Patients Treated with Janus Kinase or Interleukin-6 Inhibitors: Results of a Retrospective, Multicenter Cohort Study
Shuhei Yoshida, Masayuki Miyata, Eiji Suzuki, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 10, pp. 3000-3000
Open Access
Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study
Jiha Lee, Navasuja Kumar, Mohammed Kabeto, et al.
Drugs & Aging (2024) Vol. 41, Iss. 7, pp. 601-613
Closed Access
Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update
Xinping Tian, Qian Wang, Nan Jiang, et al.
Rheumatology and Immunology Research (2024) Vol. 5, Iss. 4, pp. 189-208
Open Access
JAK inhibitors: high risk of infectious disease in patients with RA

Reactions Weekly (2023) Vol. 1946, Iss. 1, pp. 10-10
Closed Access
Page 1

Scroll to top